Lowell L. Hart

机构：Florida Cancer Specialists & Research Institute

发表论文 208 篇 · 总被引 10537 次 · h-index 44

代表论文

• Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT (2024 · Journal of Clinical Oncology · 被引 40)
• A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors (2023 · Targeted Oncology · 被引 34)
• XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease (2023 · Breast Cancer Research · 被引 18)
• Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer (2025 · The Breast · 被引 11)
• Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2– advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, −3, and −7 trials (2025 · European Journal of Cancer · 被引 11)
• Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy (2023 · Advances in Therapy · 被引 8)